<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258488</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2020-01</org_study_id>
    <nct_id>NCT04258488</nct_id>
  </id_info>
  <brief_title>Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement</brief_title>
  <acronym>RENOVATE</acronym>
  <official_title>Randomized, Evaluation of Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joon Bum Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the long-term anticoagulation with oral factor Xa inhibitor versus&#xD;
      vitamin K antagonist in patients receiving a mechanical aortic valve replacement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with the composite of cardiac death, valve thrombosis, valve-related thromboembolic event, major bleeding, and clinically-relevant non-major bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.&#xD;
Clinically-relevant non-major bleeding is defined as BARC (Bleeding Academic Research Consortium) 2 Bleeding and major Bleeding is defined as BARC (Bleeding Academic Research Consortium) 3 or 5 Bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With all cause death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With cardiovascular death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With valve thrombosis confirmed by transthoracic echocardiography, transesophageal echocardiography, cine fluoroscopy, computed tomography, or autopsy (Valve Academic Research Consortium (VARC ) criteria)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With valve-related thromboembolic</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With transient ischemic attack</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With systemic embolism</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With major bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>BARC (Bleeding Academic Research Consortium) 3 or 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically-relevant non-major bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>BARC (Bleeding Academic Research Consortium) 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the composite of cardiac death, valve thrombosis and valve-related thromboembolic event</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the composite of cardiac death, valve thrombosis, stroke, systemic embolism and myocardial infarction event</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the composite event of major bleeding and clinically-relevant non-major bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>Clinically-relevant non-major bleeding is defined as BARC (Bleeding Academic Research Consortium) 2 Bleeding and major Bleeding is defined as BARC (Bleeding Academic Research Consortium) 3 or 5 Bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the composite of stroke, systemic embolism, transient ischemic attack and myocardial infarction event</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the composite of all-cause death, stroke, systemic embolism, transient ischemic attack and myocardial infarction event</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of echocardiographic parameter</measure>
    <time_frame>1 year</time_frame>
    <description>Integral ratio at baseline and 1 year follow-up : transaortic valve mean gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of echocardiographic parameter</measure>
    <time_frame>1 year</time_frame>
    <description>Integral ratio at baseline and 1 year follow-up : transaortic valve peak gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of echocardiographic parameter</measure>
    <time_frame>1 year</time_frame>
    <description>Integral ratio at baseline and 1 year follow-up : transaortic valve peak velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of echocardiographic parameter</measure>
    <time_frame>1 year</time_frame>
    <description>Integral ratio at baseline and 1 year follow-up : effective orifice area(EOA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>AORTIC VALVE DISEASES</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Oral Factor Xa inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K antagonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban Oral Tablet</intervention_name>
    <description>Apixaban oral tablet 5mg bid&#xD;
If age≥80, weight≤60kg, Creatinine≥1.5mg/dl OR moderate or severe renal dysfunction, Apixaban 2.5mg bid</description>
    <arm_group_label>Oral Factor Xa inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K antagonist(warfarin)</intervention_name>
    <description>Keep the international normalized ratio (INR) 2.0-3.0</description>
    <arm_group_label>Vitamin K antagonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 19 and more&#xD;
&#xD;
          2. At least 3months after mechanical aortic valve replacement&#xD;
&#xD;
          3. At least one among the conditions(as defined below) is met&#xD;
&#xD;
               -  The New York Heart Association (NYHA) Functional Classification I or II; or&#xD;
&#xD;
               -  According to the Valve Academic Research Consortium(VARC)2 criteria, confirmed&#xD;
                  proper valve function: no prosthesis-patient mismatch and mean aortic valve&#xD;
                  gradient &lt;20 mm Hg or peak velocity &lt;3 m/s, AND no moderate or severe prosthetic&#xD;
                  valve regurgitation&#xD;
&#xD;
          4. Voluntarily participated in the written agreement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Old generation mechanical valve&#xD;
&#xD;
          2. History of mechanical valve implantation in the mitral valve, pulmonary valve or&#xD;
             tricuspid valve&#xD;
&#xD;
          3. Valvular atrial fibrillation(atrial fibrillation with moderate-to-severe mitral&#xD;
             stenosis)&#xD;
&#xD;
          4. History of hemorrhagic stroke&#xD;
&#xD;
          5. Clinically overt stroke within the last 3 months&#xD;
&#xD;
          6. Renal failure(creatinine clearance &lt;15mL/min) or on hemodialysis&#xD;
&#xD;
          7. Left ventricular dysfunction: Left ventricular ejection fraction (LVEF) ≤40%&#xD;
&#xD;
          8. Moderate and severe hepatic impairment, and any hepatic disease associated with&#xD;
             coagulopathy&#xD;
&#xD;
          9. Clinically significant active bleeding&#xD;
&#xD;
         10. Bleeding or hemorrhagic disorder&#xD;
&#xD;
         11. The increased risk of bleeding due to the following reasons:&#xD;
&#xD;
               -  History of gastrointestinal ulcers or active ulcerations within the last 6 months&#xD;
&#xD;
               -  History of intracranial or intracerebral haemorrhage within the last 6 months&#xD;
&#xD;
               -  Spinal cord vascular abnormalities or intracerebral vascular abnormalities&#xD;
&#xD;
               -  History of the brain, spinal cord or ophthalmic surgery within the last 6 months&#xD;
&#xD;
               -  History of the brain or spinal cord injury within the last 6 months&#xD;
&#xD;
               -  oesophageal varices&#xD;
&#xD;
               -  Arteriovenous malformation&#xD;
&#xD;
               -  Vascular aneurysms&#xD;
&#xD;
               -  Malignant tumour with a high risk of bleeding&#xD;
&#xD;
         12. Bleeding tendencies associated with overt bleeding of;&#xD;
&#xD;
               -  gastrointestinal, genitourinary or respiratory tract;&#xD;
&#xD;
               -  cerebrovascular haemorrhage;&#xD;
&#xD;
               -  aneurysms- cerebral, dissecting aorta;&#xD;
&#xD;
               -  pericarditis and pericardial effusions;&#xD;
&#xD;
               -  bacterial endocarditis&#xD;
&#xD;
         13. Hemodynamically unstable or pulmonary embolism required thrombolysis or embolectomy&#xD;
&#xD;
         14. Combination therapy with other anticoagulants(Unfractionated heparin(UFH), enoxaparin,&#xD;
             dalteparin, fondaparinux, etc.) However, the following cases are permitted;&#xD;
&#xD;
               -  Switching anticoagulants&#xD;
&#xD;
               -  Intravenous UFH to keep central/arterial lines open&#xD;
&#xD;
         15. Uncontrolled moderate or severe hypertension&#xD;
&#xD;
         16. Gastrointestinal bleeding within 1year&#xD;
&#xD;
         17. Anaemia at least one among the conditions(as defined below) is met&#xD;
&#xD;
               -  Diagnosed and documented ongoing anaemia or&#xD;
&#xD;
               -  Hemoglobin level &lt;10.0 g/dL or platelet count &lt; 100 x 10 9/L within the last 6&#xD;
                  months&#xD;
&#xD;
         18. Infective endocarditis&#xD;
&#xD;
         19. Hypersensitivity to the main component or constituents of Apixaban or Vitamin K&#xD;
             antagonist&#xD;
&#xD;
         20. Positive pregnancy test results (all pregnant women should undergo urinary human&#xD;
             chorionic gonadotropin (hCG) testing within 7 days prior to screening and/or&#xD;
             randomization) or during pregnancy or lactation&#xD;
&#xD;
         21. Moderate to severe mitral stenosis&#xD;
&#xD;
         22. A genetic problem with galactose intolerance, Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption&#xD;
&#xD;
         23. The unsuitable condition to the protocol&#xD;
&#xD;
         24. Actively participating in another drug or device investigational study, which has not&#xD;
             completed the primary endpoint follow-up period&#xD;
&#xD;
         25. Terminal illness with life expectancy &lt;12 months&#xD;
&#xD;
         26. Vitamin K deficiency&#xD;
&#xD;
         27. Alcoholic or psychical disorder&#xD;
&#xD;
         28. Threatened abortion, eclampsia or preeclampsia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-min Ahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>drjmahn@gmail.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-hee Ham, RN</last_name>
    <phone>82230104728</phone>
    <email>cvcrc5@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Buchen Sejong Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Hee-moon Lee, MD</last_name>
      <email>rhythmists@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hee-moon Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Joon Bum Kim, MD</last_name>
      <phone>82-2-3010-5416</phone>
      <email>jbkim1975@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Joon-bum Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Hyoung-gon Je, MD</last_name>
      <email>jehg7332@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyoung-gon Je, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Bum Kim</investigator_full_name>
    <investigator_title>Professor, Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine</investigator_title>
  </responsible_party>
  <keyword>Aortic valve replacement</keyword>
  <keyword>Mechanical valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

